News | November 10, 2025
AstraZeneca delivers double-digit growth
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Glenmark will begin distribution in November 2025
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Subscribe To Our Newsletter & Stay Updated
